Inmune Bio to Host Webinar Presenting New Phase III CORDStrom Data for RDEB
Summary
Inmune Bio announced an upcoming webinar to present new Phase III clinical data for its CORDStrom™ program in recessive dystrophic epidermolysis bullosa (RDEB), highlighting systemic disease-modifying capabilities and key clinical benchmarks.
Key Events
-
Webinar to Present Phase III CORDStrom Data
Inmune Bio will host a webinar on February 26, 2026, at 1:00 p.m. ET to present new clinical data from the MissionEB Phase III clinical trial for CORDStrom™ in recessive dystrophic epidermolysis bullosa (RDEB).
-
Focus on Systemic Disease-Modifying Capabilities
The webinar will highlight CORDStrom's systemic, disease-modifying potential, moving beyond topical wound treatments, which is a significant advancement for RDEB patients.
-
Presentation of Key Clinical Benchmarks
New data will be shared on EBDASI Skin Score improvements, nutritional and weight gain in pediatric patients, reductions in pain and itch, and enhanced quality of life for RDEB patients.
Analysis
This filing announces a significant upcoming event for Inmune Bio, as it details a webinar to present new Phase III clinical data for its CORDStrom™ program in recessive dystrophic epidermolysis bullosa (RDEB). For a clinical-stage biotechnology company, Phase III data is paramount, representing the final stage before potential regulatory submission. The specific focus on systemic disease-modifying capabilities and key clinical benchmarks like EBDASI improvements, nutritional data, symptom reductions, and enhanced quality of life suggests the company anticipates positive results. This event builds on the recent 8-K filings from January 27 and February 13, which highlighted general clinical and regulatory progress. Given the company's stock is currently trading near its 52-week low, the presentation of compelling Phase III data could serve as a crucial catalyst for investor sentiment and valuation.
At the time of this filing, INMB was trading at $1.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.4M. The 52-week trading range was $1.28 to $11.64. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.